Tegid Therapeutics Inc. has identified proteolysis targeting chimera (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)-targeting moiety.

Astellas Pharma Inc. and Mitobridge Inc. have synthesized stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of autoimmune diseases, neurodegeneration, type I interferonopathy and Sjögren’s syndrome.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have disclosed zwitterionic compounds reported to be useful for the treatment of bacterial infections.

The impact of the U.S. Supreme Court’s full scope enablement ruling in Amgen Inc. v. Sanofi SA is reverberating through other genus patent challenges.

Japan Tobacco Inc. has divulged indazole compounds acting as hematopoietic prostaglandin D synthase (HPGDS) inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease, Duchenne muscular dystrophy, peripheral arterial disease, allergic rhinitis, sarcopenia and allergic asthma.

Celros Biotech Co. Ltd. has identified hydantoin derivatives acting as cytochrome b-245 heavy chain (CYBB; NOX2) and NADPH oxidase 4 (NOX4) inhibitors with blood-brain barrier permeability and metabolic stability reported to be useful for the treatment of atherosclerosis, Alzheimer’s disease, cirrhosis, diabetes, cancer, glomerulonephritis, psoriasis and rheumatoid arthritis, among others.

Assembly Biosciences Inc. has synthesized benzothiadiazepine compounds reported to be useful for the treatment of hepatitis B and hepatitis D.

Satyarx Pharma Innovations Pvt Ltd. has disclosed novel bicyclic compounds acting as DNA repair protein RAD51 homolog 1 inhibitors reported to be useful for the treatment of cancer.